{"url_path":"/sec/aard/8-k/2026-05-14/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1774857/0001193125-26-224069-index.html","accession_number":"0001193125-26-224069","cik":"0001774857","ticker":"AARD","issuer_name":"Aardvark Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1774857/0001193125-26-224069-index.html","primary_entity_key":"0001774857","primary_entity_name":"Aardvark Therapeutics, Inc."},"word_count":61,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nOn May 14, 2026, Aardvark Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has placed a full clinical hold on its investigational new drug application for ARD-101. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference."}